A Curcumin‐Based Polyherbal Slow‐Dissolving Buccal Lozenge (CBFP‐ODS) and Changes in Gingival Inflammation, Plaque Accumulation, Bleeding on Probing and Oral Malodour: A 12‐Week Prospective Single‐Arm Interventional Study in Young Adults
International Journal of Dentistry · 2026-01 · 2026 (1)
DOI: 10.1155/ijod/2236774 ↗Abstract
Background Plaque‐induced gingivitis is the most prevalent reversible inflammatory condition of the gingival tissues and remains under‐managed at the population level. Chlorhexidine, the most extensively studied chemical adjunct, is limited in sustained daily use by staining, taste alteration and mucosal effects, which motivates interest in botanically based oral wellness adjuncts intended for everyday use. This study was an uncontrolled, exploratory, hypothesis‐generating evaluation of one such adjunct. Methods We evaluated a curcumin‐based functional phytotherapeutic oral delivery system (CBFP‐ODS), a sugar‐free, slow‐dissolving buccal lozenge containing six standardised botanicals ( Curcuma longa , Ocimum sanctum , Zingiber officinale , Cinnamomum verum , Mentha piperita and Piper longum ), in adults aged 18–35 years with mild‐to‐moderate gingivitis. In a prospective, single‐arm, open‐label, pre‐ and post‐interventional study (120 enrolled), participants used one lozenge twice daily for 12 weeks while continuing routine mechanical plaque control. Outcomes at five timepoints (baseline, 1 week, 21 days, 45 days, 12 weeks) included the modified gingival index (MGI; primary outcome), the Silness and Löe Plaque Index (PI), the Ainamo and Bay Bleeding on Probing (BOP) index, an examiner‐rated organoleptic score, an adapted breath‐related self‐perception (BRSP) scale and a WHO‐adapted oral hygiene and behaviour composite. The pre‐specified primary analysis was a completer analysis of the 115 participants with complete follow‐up; a mixed‐effects model on all 120 enrolled participants was the sensitivity analysis. Results In the primary completer analysis ( n = 115), MGI decreased from 1.78 (SD 0.41) to 0.96 (SD 0.36) (mean change 0.82, 95% CI: 0.73–0.91; t (114) = 18.9; p < 0.001; Cohen’s dz ~1.76). Plaque, BOP, oral malodour and self‐perceived breath showed within‐subject reductions of ~43%–53%, and the behavioural composite increased by ~31% (all p < 0.001). The mixed‐effects sensitivity analysis on all 120 enrolled participants gave a concordant estimated reduction of 0.81 MGI units (95% CI: 0.73–0.89). No product‐related adverse events were recorded. Conclusions In this single‐arm study, twice‐daily use of CBFP‐ODS was associated with within‐subject improvements in gingival, plaque, bleeding and breath‐related outcomes over 12 weeks. Because the design was uncontrolled and open‐label, these observations cannot separate the effect of the intervention from improved oral hygiene behaviour, participation effects, regression to the mean or natural clinical variation and are hypothesis‐generating. They do not demonstrate efficacy or verify mucosal absorption. Randomised, placebo‐controlled and active‐controlled trials are required before any statement about efficacy can be made. Trial Registration: Clinical Trials Registry, India: (CTRI/2025/06/088964; prospectively registered)
EUVIMED